The first patient in a trial of Abbott's minimally invasive, clip-based transcatheter valve repair system for the treatment of severe tricuspid regurgitation has been enrolled at Abbott Northwestern Hospital in Minneapolis. The study, which will include 75 symptomatic patients at 25 European and US sites, is expected to support CE mark approval of the system in the EU.
Trial begins for Abbott's transcatheter tricuspid repair device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.